Evelo Biosciences Reviewing Alternatives After Study Didn't Meet Endpoint
By Will Feuer Evelo Biosciences said it is reviewing strategic alternatives after its Phase 2 clinical trial of EDP2939 for the treatment of moderate...
Source: marketwatch.com